Utah Retirement Systems raised its position in Boston Scientific Corporation (NYSE:BSX) by 1.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 250,705 shares of the medical equipment provider’s stock after buying an additional 3,900 shares during the period. Utah Retirement Systems’ holdings in Boston Scientific Corporation were worth $6,950,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Boston Scientific Corporation by 15.9% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 320,517 shares of the medical equipment provider’s stock valued at $8,885,000 after buying an additional 43,975 shares during the period. Andra AP fonden raised its stake in shares of Boston Scientific Corporation by 2.5% in the second quarter. Andra AP fonden now owns 211,300 shares of the medical equipment provider’s stock valued at $5,857,000 after buying an additional 5,100 shares during the period. Aviva PLC raised its stake in shares of Boston Scientific Corporation by 1.3% in the second quarter. Aviva PLC now owns 853,328 shares of the medical equipment provider’s stock valued at $23,654,000 after buying an additional 11,025 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Boston Scientific Corporation by 2.0% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,108,006 shares of the medical equipment provider’s stock valued at $113,874,000 after buying an additional 81,531 shares during the period. Finally, Peddock Capital Advisors LLC purchased a new stake in shares of Boston Scientific Corporation during the second quarter valued at $201,000. Institutional investors own 91.62% of the company’s stock.

Shares of Boston Scientific Corporation (BSX) opened at 26.72 on Friday. The company has a 50-day moving average price of $27.08 and a 200-day moving average price of $26.22. The company has a market cap of $36.66 billion, a P/E ratio of 47.80 and a beta of 1.09. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.27 earnings per share. On average, equities analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/27/boston-scientific-corporation-bsx-stake-increased-by-utah-retirement-systems.html.

Several equities research analysts recently weighed in on BSX shares. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific Corporation in a report on Sunday, July 30th. Goldman Sachs Group, Inc. (The) started coverage on Boston Scientific Corporation in a report on Tuesday, May 16th. They issued a “neutral” rating and a $28.00 price objective for the company. J P Morgan Chase & Co reissued an “overweight” rating and issued a $31.00 price objective (up previously from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, May 1st. Finally, BidaskClub lowered Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $30.06.

In other news, EVP Timothy A. Pratt sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $27.13, for a total value of $271,300.00. Following the completion of the sale, the executive vice president now directly owns 215,846 shares in the company, valued at $5,855,901.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Wendy Carruthers sold 12,433 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $26.75, for a total value of $332,582.75. The disclosure for this sale can be found here. Insiders sold 207,625 shares of company stock valued at $5,686,383 over the last 90 days. Company insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.